Expand ENSC Menu
ENSC MENU

ENSC Latest Press Releases

-- June 26, 2026 --

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study ACCESS Newswire 8:00 AM

-- May 15, 2026 --

Ensysce Biosciences Reports First Quarter 2026 Financial Results ACCESS Newswire 4:15 PM

-- May 12, 2026 --

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology ACCESS Newswire 8:00 AM

-- May 8, 2026 --

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam ACCESS Newswire 8:00 AM

-- April 16, 2026 --

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study ACCESS Newswire 8:05 AM

-- April 7, 2026 --

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs ACCESS Newswire 8:00 AM

-- March 30, 2026 --

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results ACCESS Newswire 4:50 PM

-- March 4, 2026 --

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans ACCESS Newswire 8:45 AM

-- March 3, 2026 --

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology ACCESS Newswire 8:00 AM

-- February 27, 2026 --

Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength Globe Newswire 9:45 AM

-- February 25, 2026 --

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value ACCESS Newswire 8:00 AM

-- February 23, 2026 --

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events ACCESS Newswire 8:00 AM

-- January 28, 2026 --

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain ACCESS Newswire 8:00 AM
Market Data Delayed 15 Minutes